Calixarene-Embedded Nanoparticles for Interference-Free Gene-Drug Combination Cancer Therapy

Liu, Q (Liu, Qi)^{[ 1,2 ]} ; Zhang, TX (Zhang, Tian-Xing)^{[ 3 ]} ; Zheng, YD (Zheng, Yadan)^{[ 1,2 ]} ; Wang, C (Wang, Chun)^{[ 1,2 ]} ; Kang, ZY (Kang, Ziyao)^{[ 1,2 ]} ; Zhao, Y (Zhao, Yu)^{[ 1,2 ]} ; Chai, JS (Chai, Jingshan)^{[ 1,2 ]} ; Li, HB (Li, Hua-Bin)^{[ 3 ]} ; Guo, DS (Guo, Dong-Sheng)^{[ 3 ]} ; Liu, Y (Liu, Yang)^{[ 1,2 ]} ; Shi, LQ (Shi, Linqi)^{[ 1,2 ]} ...更少内容

SMALL, 2021, 文献号: 2006223

DOI: 10.1002/smll.202006223

摘要

Combination therapy based on molecular drugs and therapeutic genes provides an effective strategy for malignant tumor treatment. However, effective gene and drug combinations for cancer treatment are limited by the widespread antagonism between therapeutic genes and molecular drugs. Herein, a calixarene-embedded nanoparticle (CENP) is developed to co-deliver molecular drugs and therapeutic genes without compromising their biological functions, thereby achieving interference-free gene-drug combination cancer therapy. CENP is composed of a cationic polyplex core and an acid-responsive polymer shell, allowing CENP loading and delivering therapeutic genes with improved circulation stability and enhanced tumor accumulation. Moreover, the introduction of carboxylated azocalix[4]arene, which is a hypoxia-responsive calixarene derivatives, in the polyplex core endows CENP with the capability to load molecular drugs through the host-guest complexation as well as inhibit the interference between the drugs and genes by encapsulating the drugs into its cavity. By loading doxorubicin and a plasmid DNA-based CRISPR interference system that targets miR-21, CENP exhibits the significantly enhanced anti-tumor effects in mice. Considering the wide variety of calixarene derivatives, CENP can be adapted to deliver almost any combination of drugs and genes, providing the potential as a universal platform for the development of interference-free gene-drug combination cancer therapy.